Kolik L G, Nadorova A V, Seredenin S B
V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
Bull Exp Biol Med. 2017 Dec;164(2):152-157. doi: 10.1007/s10517-017-3946-0. Epub 2017 Nov 27.
Activity of hemantane, an amino adamantane derivative, exhibiting the properties of lowaffinity non-competitive NMDA receptor antagonist, was evaluated in experimental in vivo models of alcoholism. Hemantane had no effects on the formation and manifestation of behavioral sensitization to ethanol in DBA/2 mice. Under conditions of free choice between 10% ethanol and water, hemantane (20 mg/kg/day for 14 days, intraperitoneally) significantly reduced the daily ethanol intake in random-bred male rats with formed alcohol motivation (>4 g/kg of ethanol). During modelling of withdrawal syndrome, hemantane administered intraperitoneally in doses of 5-20 mg/kg dose-dependently attenuated alcohol-deprivation effect after acute withdrawal with no effects on protracted abstinence. It was found that hemantane suppressed alcohol drinking behavior in long-term ethanol experienced rats and attenuated alcohol-seeking behavior after acute withdrawal.
金刚乙胺（一种氨基金刚烷衍生物，具有低亲和力非竞争性NMDA受体拮抗剂的特性）在酒精中毒的实验体内模型中进行了活性评估。金刚乙胺对DBA/2小鼠对乙醇行为敏化的形成和表现没有影响。在10%乙醇和水之间自由选择的条件下，金刚乙胺（20mg/kg/天，连续14天，腹腔注射）显著降低了具有形成的酒精动机（>4g/kg乙醇）的随机繁殖雄性大鼠的每日乙醇摄入量。在戒断综合征建模期间，腹腔注射5-20mg/kg剂量的金刚乙胺剂量依赖性地减轻了急性戒断后的酒精剥夺效应，对长期戒断没有影响。研究发现，金刚乙胺抑制了长期摄入乙醇大鼠的饮酒行为，并减轻了急性戒断后的觅酒行为。
